VXRT
Vaxart, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.43
+1.27%Oct 29, 2026, 12:00 UTC
Vaxart announced that it will report its third-quarter 2026 financial results on November 5, 2026.
Source:Oct 29, 2026, 12:00 UTC
Vaxart announced that its senior management team will participate in a virtual stockholder fireside chat on November 6, 2026, at 4:30 p.m. ET.
Source:Aug 9, 2026, 20:04 UTC
Vaxart reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial during its Q2 earnings call.
Source:Jul 20, 2026, 10:02 UTC
Vaxart held its 2026 Annual Meeting of Stockholders, where investors re-elected the company's full slate of directors.
Jul 2, 2026, 00:00 UTC
Vaxart entered into a cooperation agreement with a stockholder group, withdrawing director nominations and agreeing to appoint an independent director and adopt new policies.
Source: